Leslie Lappalainen1,2, Seonaid Nolan1,3, Sabina Dobrer1, Cathy Puscas1,4, Julio Montaner1,3, Keith Ahamad1,2, Huiru Dong1, Thomas Kerr1,3, Evan Wood1,3, M-J Milloy1,3. 1. British Columbia Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, Canada. 2. Department of Family Medicine, University of British Columbia, Vancouver, Canada. 3. Department of Medicine, University of British Columbia, Vancouver, Canada. 4. Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Abstract
BACKGROUND AND AIMS: For HIV-positive individuals who use illicit opioids, engagement in methadone maintenance therapy (MMT) can contribute to improved HIV treatment outcomes. However, to our knowledge, the role of methadone dosing in adherence to antiretroviral therapy (ART) has not yet been investigated. We sought to examine the relationship between methadone dose and ART adherence among a cohort of people who use illicit opioids. DESIGN AND SETTING: We used data from the AIDS Care Cohort to Evaluate Access to Survival Services (ACCESS) study, an ongoing prospective observational cohort of HIV-positive people who use illicit drugs in Vancouver, Canada, linked confidentially to comprehensive HIV treatment data in a setting of universal no-cost medical care, including medications. We evaluated the longitudinal relationship between methadone dose and the likelihood of ≥ 95% adherence to ART among ART-exposed participants during periods of engagement in MMT. PARTICIPANTS: Two hundred and ninety-seven ART-exposed individuals on MMT were recruited between December 2005 and May 2013 and followed for a median of 42.1 months. MEASUREMENTS: We measured methadone dose at ≥ 100 versus < 100 mg/day and the likelihood of ≥ 95% adherence to ART. FINDINGS: In adjusted generalized estimating equation (GEE) analyses, MMT dose ≥ 100 mg/day was associated independently with optimal adherence to ART [adjusted odds ratio (AOR) = 1.38; 95% confidence interval (CI) = 1.08-1.77). In a subanalysis, we observed a dose-response relationship between increasing MMT dose and ART adherence (AOR = 1.06 per 20 mg/day increase, 95% CI = 1.00-1.12). CONCLUSION: Among HIV-positive individuals in methadone maintenance therapy, those receiving higher doses of methadone (≥ 100 mg/day) are more likely to achieve ≥ 95% adherence to antiretroviral therapy than those receiving lower doses.
BACKGROUND AND AIMS: For HIV-positive individuals who use illicit opioids, engagement in methadone maintenance therapy (MMT) can contribute to improved HIV treatment outcomes. However, to our knowledge, the role of methadone dosing in adherence to antiretroviral therapy (ART) has not yet been investigated. We sought to examine the relationship between methadone dose and ART adherence among a cohort of people who use illicit opioids. DESIGN AND SETTING: We used data from the AIDS Care Cohort to Evaluate Access to Survival Services (ACCESS) study, an ongoing prospective observational cohort of HIV-positivepeople who use illicit drugs in Vancouver, Canada, linked confidentially to comprehensive HIV treatment data in a setting of universal no-cost medical care, including medications. We evaluated the longitudinal relationship between methadone dose and the likelihood of ≥ 95% adherence to ART among ART-exposed participants during periods of engagement in MMT. PARTICIPANTS: Two hundred and ninety-seven ART-exposed individuals on MMT were recruited between December 2005 and May 2013 and followed for a median of 42.1 months. MEASUREMENTS: We measured methadone dose at ≥ 100 versus < 100 mg/day and the likelihood of ≥ 95% adherence to ART. FINDINGS: In adjusted generalized estimating equation (GEE) analyses, MMT dose ≥ 100 mg/day was associated independently with optimal adherence to ART [adjusted odds ratio (AOR) = 1.38; 95% confidence interval (CI) = 1.08-1.77). In a subanalysis, we observed a dose-response relationship between increasing MMT dose and ART adherence (AOR = 1.06 per 20 mg/day increase, 95% CI = 1.00-1.12). CONCLUSION: Among HIV-positive individuals in methadone maintenance therapy, those receiving higher doses of methadone (≥ 100 mg/day) are more likely to achieve ≥ 95% adherence to antiretroviral therapy than those receiving lower doses.
Authors: Julia H Arnsten; Penelope A Demas; Richard W Grant; Marc N Gourevitch; Homayoon Farzadegan; Andrea A Howard; Ellie E Schoenbaum Journal: J Gen Intern Med Date: 2002-05 Impact factor: 5.128
Authors: Jean B Nachega; Olalekan A Uthman; Karl Peltzer; Lindsey A Richardson; Edward J Mills; Kofi Amekudzi; Alice Ouédraogo Journal: Bull World Health Organ Date: 2014-10-30 Impact factor: 9.408
Authors: Mary Clare Kennedy; Thomas H Kerr; Evan Wood; Jeannie A Shoveller; Julio S G Montaner; M-J S Milloy Journal: AIDS Date: 2018-05-15 Impact factor: 4.177
Authors: M Eugenia Socías; Evan Wood; Will Small; Huiru Dong; Jean Shoveller; Thomas Kerr; Julio Montaner; M-J Milloy Journal: Drug Alcohol Depend Date: 2016-09-20 Impact factor: 4.492
Authors: N A Mohd Salleh; N Fairbairn; S Nolan; R Barrios; J Shoveller; L Richardson; M-J Milloy Journal: HIV Med Date: 2019-07-29 Impact factor: 3.180
Authors: Nur Afiqah Mohd Salleh; Lindsey Richardson; Thomas Kerr; Jean Shoveller; Julio Montaner; Adeeba Kamarulzaman; M-J Milloy Journal: J Addict Med Date: 2018 Jul/Aug Impact factor: 3.702
Authors: E J Edelman; K S Gordon; J P Tate; W C Becker; K Bryant; K Crothers; J R Gaither; C L Gibert; A J Gordon; Bdl Marshall; M C Rodriguez-Barradas; J H Samet; M Skanderson; A C Justice; D A Fiellin Journal: HIV Med Date: 2016-11 Impact factor: 3.180